The evidence base for ICS/formoterol maintenance and reliever therapy in severe asthma

Richard Beasley; Jonathan Noble; Mark Weatherall

doi:10.1183/13993003.00523-2024

The evidence base for ICS/formoterol maintenance and reliever therapy in severe asthma

Eur Respir J. 2024 Jun 20;63(6):2400523. doi: 10.1183/13993003.00523-2024. Print 2024 Jun.

Authors

Richard Beasley¹, Jonathan Noble², Mark Weatherall³

Affiliations

¹ Medical Research Institute of New Zealand, Wellington, New Zealand Richard.Beasley@mrinz.ac.nz.
² Medical Research Institute of New Zealand, Wellington, New Zealand.
³ University of Otago Wellington, Wellington, New Zealand.

Abstract

ICS/formoterol MART is an evidence-based alternative to high dose ICS/LABA in asthma patients at high risk of severe exacerbations; limited generalisability of RCTs to severe asthma registries applies similarly to high dose ICS/LABA therapy as to MART https://bit.ly/4aVFrNH

Publication types

Editorial
Letter
Comment

MeSH terms

Administration, Inhalation
Adrenal Cortex Hormones / administration & dosage
Adrenal Cortex Hormones / therapeutic use
Anti-Asthmatic Agents* / administration & dosage
Anti-Asthmatic Agents* / therapeutic use
Asthma* / drug therapy
Bronchodilator Agents / administration & dosage
Bronchodilator Agents / therapeutic use
Ethanolamines* / administration & dosage
Ethanolamines* / therapeutic use
Evidence-Based Medicine
Formoterol Fumarate* / administration & dosage
Formoterol Fumarate* / therapeutic use
Humans
Treatment Outcome

Substances

Formoterol Fumarate
Anti-Asthmatic Agents
Ethanolamines
Adrenal Cortex Hormones
Bronchodilator Agents